Risks and benefits of aerosolized pentamidine and cotrimoxazole in primary prophylaxis of Pneumocystis carinii pneumonia in HIV-1-infected patients: A two-year Italian multicentric randomized controlled trial

Journal of Infection

Volumn 32, Issue 2, 1996, Pages 123-131

  Rizzardi, G P ^a   Lazzarin, A ^a,b,e   Musicco, M ^c   Frigerio, D ^d   Maillard, M ^b   Lucchini, M ^d   Moroni, M ^f  

^a UNIVERSITY OF MILAN   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c CNR   (Italy)

^d Medical Department Rhöne Poulenc Rorer   (Italy)

^e SAN RAFFAELE HOSPITAL   (Italy)

^f NONE

Author keywords

[No Author keywords available]

Indexed keywords

COTRIFAMOLE; PENTAMIDINE ISETHIONATE; SULFAMETHOXAZOLE; TRIMETHOPRIM;

ADULT; ARTICLE; CELL COUNT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST BENEFIT ANALYSIS; DRUG EFFICACY; DRUG MIXTURE; DRUG SAFETY; ENCEPHALITIS; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; INHALATIONAL DRUG ADMINISTRATION; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTICENTER STUDY; OPPORTUNISTIC INFECTION; ORAL DRUG ADMINISTRATION; PNEUMOCYSTIS PNEUMONIA; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SURVIVAL; TOXOPLASMA;

ADULT; AEROSOLS; AIDS-RELATED OPPORTUNISTIC INFECTIONS; FEMALE; HIV-1; HUMANS; MALE; PENTAMIDINE; PNEUMONIA, PNEUMOCYSTIS; TOXOPLASMOSIS, CEREBRAL; TRIMETHOPRIM-SULFAMETHOXAZOLE COMBINATION;

EID: 0029939801     PISSN: 01634453     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0163-4453(96)91312-2     Document Type: Review

References (49)

1. Murray JF, Garay SM, Hopewell PC, Mills J, Snider JL, Stover DE. Pulmonary complications of the acquired immunodeficiency syndrome: an update: report of the second National Heart, Lung and Blood Institute workshop. Am Rev Respir Dis 1987; 135: 504-509.
2. Selik RM, Starcher ET, Curran JW. Opportunistic diseases reported in AIDS patients: frequencies, associations, and trends. AIDS 1987; 1: 175-182.
3. Centers for Disease Control. Guidelines for prophylaxis against Pneumocystis carinii pneumonia for persons infected with HIV. JAMA 1989; 262: 335-339.
4. Kovacs JA, Hiemanz JW, Macher AM et al. Pneumocystis carinii pneumonia: a comparison between patients with the acquired immunodeficiency syndrome and patients with other immunodeficiencies. Ann Intern Med 1984; 100: 663-671.
5. Kovacs JA, Masur H. Prophylaxis of Pneumocystis carinii pneumonia: an update. J Infect Dis 1989; 160: 882-886.
6. Recommendations for prophylaxis against Pneumocystis carinii pneumonia for persons infected with Human Immunodeficiency Virus. U.S. Public Health Service Task Force on antipneumocystis prophylaxis in patients with Human Immunodeficiency Virus infection. J Acquir Immune Defic Syndr 1993; 6: 46-55.
7. Murray JF, Felton CP, Garay SM et al. Pulmonary complications of the acquired immunodeficiency syndrome: report of a National Heart, Lung, and Blood Institute workshop. N Engl J Med 1984; 310: 1682-1688.
8. Glatt AE, Chirgwin K, Landesman SH. Treatment of infections associated with human immunodeficiency virus. N Engl J Med 1988; 318: 1439-1448.
9. Masur H, Ognibene FP, Yarchoan R et al. CD4 count as predictors of opportunistic pneumonias in human immunodeficiency virus (HIV) infection. Ann Intern Med 1989; 111: 223-231.
10. Phair J, Muñoz A, Detels R et al. The risk of Pneumocystis carinii pneumonia among men infected with human immunodeficiency virus type 1. N Engl J Med 1990; 322: 161-165.
11. Crowe SM, Carlin JB, Stewart KI, Lucas CR, Hoy JF. Predictive value of CD4 lymphocyte numbers for the development of opportunistic infections and malignancies in HIV-infected persons. J Acquir Immune Defic Syndr 1991; 4: 770-776.
12. Graham NMH, Zeger SL, Park LP et al. Effect of zidovudine and Pneumocystis carinii pneumonia prophylaxis on progression of HIV-1 infection to AIDS. Lancet 1991; 338: 265-269.
13. Hoover DR, Saah AJ, Bacellar H et al. Clinical manifestations of AIDS in the era of pneumocystis prophylaxis. N Engl J Med 1993; 329: 1922-1926.
14. Fischl MA, Richman DD, Grieco MH et al. The efficacy of azydothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex: a double-blind placebo-controlled trial. N Engl J Med 1987; 317: 185-191.
15. Fischl MA, Richman DD, Hansen N et al. The safety and efficacy of zidovudine (AZT) in the treatment of patients with mildly symptomatic human immunodeficiency virus type 1 (HIV) infection: a double-blind placebo-controlled trial. Ann Intern Med 1990; 112: 727-737.
16. Leoung GS, Feigal DW Jr., Montgomery AB et al. Aerosolized pentamidine for prophylaxis against Pneumocystis carinii pneumonia: the San Francisco Community Prophylaxis Trial. N Engl J Med 1990; 323: 769-775.
17. Schneider NME, Hoepelman AIM, Eeftinck Schattenkerk JKM et al. A controlled trial of aerosolized pentamidine or trimethoprim-sulfamethoxazole as primary prophylaxis against Pneumocystis carinii pneumonia in patients with human immunodeficiency virus infection. N Engl J Med 1992; 327: 1836-1841.
18. Hardy WD, Feinberg J, Finkelstein DM et al. A controlled trial of trimethoprim-sulfamethoxazole or aerosolized pentamidine for secondary prophylaxis of Pneumocystis carinii pneumonia in patients with the acquired immunodeficiency syndrome. N Engl J Med 1992; 327: 1842-1848.
19. Hirschel B, Lazzarin A, Chopard P et al. A controlled trial of inhaled pentamidine for primary prevention of Pneumocystis carinii pneumonia. N Engl J Med 1991; 324: 1079-1083.
20. Fischl MA, Dickinson GM, La Voie L. Safety and efficacy of sulfamethoxazole and trimethoprim chemoprophylaxis for Pneumocystis carinii pneumonia in AIDS. JAMA 1988; 259: 1185-1189.
21. Ruskin J, LaRiviere M. Low-dose co-trimoxazole for prevention of Pneumocystis carinii pneumonia in human immunodeficiency virus disease. Lancet 1991; 337: 468-471.
22. Hughes WT, Kuhn S, Chaudhary S et al. Successful chemoprophylaxis for Pneumocystis carinii pneumonitis. N Engl J Med 1977; 297: 1419-1426.
23. Hughes WT, Rivera GK, Schell MJ, Thornton D, Lott L. Successful intermittent chemoprophylaxis for Pneumocystis carinii pneumonitis. N Engl J Med 1987; 316: 1627-1632.
24. Murphy RL, Lavelle JP, Allan JD et al. Aerosol pentamidine prophylaxis following Pneumocystis carinii pneumonia in AIDS patients: results of a blinded dose-comparison study using an ultrasonic nebulizer. Am J Med 1991; 90: 418-426.
25. Girard PM, Landman R, Gaudebout C et al. Prevention of Pneumocystis carinii pneumonia relapse by pentamidine aerosol in zidovudine-treated AIDS patients. Lancet 1989; 1: 1348-1353.
26. Montaner JSG, Lawson LM, Gervais A et al. Aerosol pentamidine for secondary prophylaxis of AIDS-related Pneumocystis carinii pneumonia: a randomized, placebo-controlled study. Ann Intern Med 1991; 114: 948-953.
27. Golden JA, Chernoff D, Hollander H, Feigal D, Conte JE. Prevention of Pneumocystis carinii pneumonia by inhaled pentamidine. Lancet 1989; 1: 654-657.
28. Carr A, Tindall B, Penny R, Cooper D. Trimethoprim-sulphamethoxazole appears more effective than aerosolized pentamidine as secondary prophylaxis against Pneumocystis carinii pneumonia in patients with AIDS. AIDS 1992; 6: 165-171.
29. Bozzette SA, Finkelstein DM, Spector SA et al. A randomized trial of three antipneumocystis agents in patients with advanced human immunodeficiency virus infection. N Engl J Med 1995; 332: 693-699.
30. Vohringer HF, Arasteh K, Link H, Ehninger G, Hardtmann I. Determinants of serum pentamidine concentration in the human. Med Klin 1992; 87 (Suppl. 1): 24-29.
31. Centers for Disease Control. Revision of the CDC surveillance case-definition for acquired immunodeficiency syndrome. MMWR 1987; 36 (Suppl. 1S): 3S-15S.
32. Freedman LS. Tables of the numbers of patients required in clinical trials using the log-rank test. Stat in Med 1982; 1: 121-129.
33. Kaplan EL, Meier P. Non parametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-481.
34. Cox DR. Regression model and life tables. JR Statis Soc [B] 1972; 34: 187-220.
35. Antinori A, Murri R, Tamburrini E, De Luca A, Ortona L. Failure of low-dose dapsone-pyrimethamine in primary prophylaxis of Pneumocystis carinii pneumonia. Lancet 1992; 340: 788.
36. Mallolas J, Zamora L, Gatell JM et al. Primary prophylaxis for Pneumocystis carinii pneumonia: a randomized trial comparing cotrimoxazole, aerosolized pentamidine and dapsone plus pyrimethamine. AIDS 1993; 7: 59-64.
37. May T, Beuscart C, Reynes J et al. Trimethoprim-sulfamethoxazole versus aerosolized pentamidine for primary prophylaxis of Pneumocystis carinii pneumonia: a prospective, randomized, controlled clinical trial. J AIDS 1994; 7: 457-462.
38. Ong ELC, Dunbar EM, Mandal BK. Efficacy and effects on pulmonary function tests of weekly 600 mg aerosol pentamidine as prophylaxis against Pneumocystis carinii pneumonia. Infection 1992; 20: 136-139.
39. Golden JA, Katz MH, Chernoff DN. Duncan SM, Conte JE Jr. A randomized comparison of once-monthly or twice-monthly high-dose aerosolized pentamidine prophylaxis. Chest 1993; 104: 743-750.
40. Rizzardi GP, Lazzarin A, Musicco M et al. Better efficacy of twice-monthly than once-monthly aerosolized pentamidine for secondary prophylaxis of Pneumocystis carinii pneumonia in patients with the acquired immunodeficiency syndrome: an Italian multicentric randomized controlled trial. J Infection 1995, (in press).
41. Pretet S, Salmon D, Rousseau F et al. Long-term results of monthly inhaled pentamidine as primary prophylaxis of Pneumocystis carinii pneumonia in HIV-infected patients. Am J Med 1993; 94: 35-40.
42. Girard PM, Landman R, Gaudebout C et al. Dapsone-pyrimethamine compared with aerosolized pentamidine as primary prophylaxis against Pneumocystis carinii pneumonia and toxoplasmosis in HIV infection. N Engl J Med 1993; 328: 1514-1520.
43. Tournerie C, Charreau I. Cotrimoxazole for primary prophylaxis of toxoplasma encephalitis in advanced HIV patients. IXth International Conference on AIDS. Berlin, Germany, 1993: Abst. WS-B13-2.
44. Stein DS, Stevens RC, Terry D et al. Use of low-dose trimethoprim-sulfamethoxazole thrice weekly for primary and secondary prophylaxis of Pneumocystis carinii pneumonia in human immunodeficiency virus-infected patients. Antimicrob Agents Chemother 1991; 35: 1705-1709.
45. Narciso P, Alba L, Antonelli L et al. A comparison of efficacy and tolerability of four different drug regimens for primary and secondary prophylaxis of Pneumocystis carinii pneumonia in HIV-infected patients. VIIIth International Conference on AIDS. Amsterdam, The Netherlands, 1992: Abst. PoB 3313.
46. Lemp GF, Payne SF, Neal D, Temelso R, Rutherford GW. Survival trends for patients with AIDS. JAMA 1990; 263: 402-406.
47. Volberding PA, Lagakos SW, Coch MA et al. Zidovudine in asymptomatic human immunodeficiency virus infection: a controlled trial in persons with fewer than 500 CD4-positive cells per cubic millimiter. N Engl J Med 1990; 322: 941-949.
48. Hughes WT. A new drug (566C80) for the treatment of Pneumocystis carinii pneumonia. Ann Intern Med 1992; 116: 953-954.
49. Hughes WT, Leoung G, Kramer F et al. Comparison to atovaquone (566C80) with trimethoprim-sulfamethoxazole to treat Pneumocystis carinii pneumonia in patients with AIDS. N Engl J Med 1993; 328: 1521-1527.